Αρχική World News Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer

Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer

In a multicenter, phase III, randomised DAWNA-1 study, the combination of dalpiciclib, a new cyclin-dependent kinase (CDK) 4 and 6 inhibitor, with fulvestrant improved progression-free survival (PFS) with manageable safety in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer who progressed or relapsed on endocrine therapy. The researchers from the DAWNA-1 Study Consortium led by doctors from the Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, China, who reported the interim results on 4 November 2021 in the Nature Medicine wrote that their findings support the application of dalpiciclib plus fulvestrant as a new treatment option for patients with HR-positive, HER2-negative advanced breast cancer who relapse or progress on previous endocrine therapy.

Dalpiciclib (SHR6390) is a new, orally administered, selective CDK4/6 inhibitor. In preclinical studies, dalpiciclib was shown to exert potent antitumour activity via retinoblastoma protein-dependent cytostasis. Dalpiciclib as monotherapy has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated HR-positive, HER2-negative advanced breast cancer. In a phase Ib study, the researchers established the synergic effects of dalpiciclib with fulvestrant in the treatment of advanced breast cancer.

The DAWNA-1 investigators conducted a randomised, double-blind, placebo-controlled phase III study to further assess the efficacy and safety of dalpiciclib plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer who relapsed or progressed on previous endocrine therapy.

In total, 361 patients were randomised 2:1 to receive dalpiciclib plus fulvestrant or placebo plus fulvestrant. The study met the primary endpoint, showing significantly prolonged PFS assessed by investigators with dalpiciclib plus fulvestrant (15.7 months, 95% confidence interval (CI) 11.1–not reached) versus placebo plus fulvestrant (7.2 months, 95% CI 5.6–9.2) with hazard ratio 0.42 (95% CI 0.31–0.58; one-sided p < 0.0001).

The most common grade 3 or 4 adverse events with dalpiciclib plus fulvestrant were neutropenia (84.2%) and leukopenia (62.1%). The incidence of serious adverse events was 5.8% with dalpiciclib plus fulvestrant versus 6.7% with placebo plus fulvestrant.

The study team resported some limitations. Only patients with HR-positive, HER2-negative advanced breast cancer and secondary endocrine resistance were enroled. The role of dalpiciclib combination therapy in the treatment of patients with primary endocrine resistance requires further investigation. The study was conducted in Chinese patients and the efficacy and tolerability of dalpiciclib plus fulvestrant in other populations is to be established. The overall survival data are not mature yet. The long-term survival benefits of adding dalpiciclib to fulvestrant will be further elucidated in final analysis of the study.

The authors concluded that their findings support the application of dalpiciclib plus fulvestrant as a new treatment option for patients with HR-positive, HER2-negative advanced breast cancer who relapse or progress on previous endocrine therapy.

The study was funded by Jiangsu Hengrui Pharmaceuticals (formerly Jiangsu Hengrui Medicine).


Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nature Medicine 2021;27:1904-1909.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...